Morten Borg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Morten Borg has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
Ole Hilberg
Department of Medicine, Lillebaelt Hospital, Vejle, Denmark
16 shared publications- Ole Hilberg
Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
14 shared publications Anders Løkke
Department of Medicine, Lillebaelt Hospital, Vejle, Denmark
13 shared publicationsRikke Ibsen
I2Minds, Aarhus C, Denmark
11 shared publications- Sara Witting Christensen Wen
Department of Regional Health Research, University of Southern Denmark, Campusvej 55, Odense M 5230, Denmark; Department of Biochemistry and Immunology, Lillebælt Hospital Vejle, Beriderbakken 4, Vejle 7100, Denmark
8 shared publications - Anders Løkke
Department of Medicine, Little Belt Hospital, 7100 Vejle, Denmark
6 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e004269
Nationwide study of blood eosinophils in COPD: impact of exacerbations and corticosteroids
- 26 October 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e004269
Open AccessNationwide study of blood eosinophils in COPD: impact of exacerbations and corticosteroids
- Open Access
- 20 August 2026
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 28 (11) , 871-881
Diagnostic Performance of a Multiplex Circulating Tumor DNA Assay for Lung Cancer Detection
- 20 August 2026
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 28 (11) , 871-881
Open AccessDiagnostic Performance of a Multiplex Circulating Tumor DNA Assay for Lung Cancer Detection
- Open Access
- 21 July 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 152 (10)
The prognostic potential of an immunology score in patients treated with curative surgery for non-small cell lung cancer
Purpose: Curative surgery is the best treatment for patients with early-stage non-small cell lung cancer (NSCLC), but around 40% experience recurrence impacting survival. Does the individual immunological status affect the prognosis? This study investigated four immunology markers in relation to recurrence and survival after curative surgery for NSCLC. Methods: Natural Killer cell activity (NKA), C-reactive protein (CRP), Interleukin 6 (IL6) and Transforming growth factor beta (TGFβ) were analysed before surgery and at three months after surgery for NSCLC. Results: Of the 103 enrolled patients, 43 experienced recurrence over a period of median 71 months. The biomarkers were unsuitable for detecting recurrence with area under the receiver operating characteristics curve ranging from 0.52 to 0.58. Baseline CRP and TGFβ were significantly associated with overall survival (OS), and a score based on all four biomarkers demonstrated statistically significant prognostic impact on both recurrence free survival (RFS) and OS. The biomarker score was an independent prognostic factor when adjusting for stage and surgery type, hazard ratio 3.18 (95% CI 1.53–6.61, p = 0.002) for OS with borderline significance for RFS, hazard ratio 1.93 (95% CI 1.06–3.51, p = 0.032). Conclusion: Individually, NKA, CRP, IL6 and TGFβ were not suited for predicting disease recurrence after curative surgery for NSCLC. However, the combined biomarker score was significantly associated with OS. The score may give an indication of the immunological status of the patient, which could be useful for pre- or post-surgery assessment, in relation to immunotherapy or other oncologic treatments if future studies can prove clinical utility.
- 21 July 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 152 (10)
Open AccessThe prognostic potential of an immunology score in patients treated with curative surgery for non-small cell lung cancer
Purpose: Curative surgery is the best treatment for patients with early-stage non-small cell lung cancer (NSCLC), but around 40% experience recurrence impacting survival. Does the individual immunological status affect the prognosis? This study investigated four immunology markers in relation to recurrence and survival after curative surgery for NSCLC. Methods: Natural Killer cell activity (NKA), C-reactive protein (CRP), Interleukin 6 (IL6) and Transforming growth factor beta (TGFβ) were analysed before surgery and at three months after surgery for NSCLC. Results: Of the 103 enrolled patients, 43 experienced recurrence over a period of median 71 months. The biomarkers were unsuitable for detecting recurrence with area under the receiver operating characteristics curve ranging from 0.52 to 0.58. Baseline CRP and TGFβ were significantly associated with overall survival (OS), and a score based on all four biomarkers demonstrated statistically significant prognostic impact on both recurrence free survival (RFS) and OS. The biomarker score was an independent prognostic factor when adjusting for stage and surgery type, hazard ratio 3.18 (95% CI 1.53–6.61, p = 0.002) for OS with borderline significance for RFS, hazard ratio 1.93 (95% CI 1.06–3.51, p = 0.032). Conclusion: Individually, NKA, CRP, IL6 and TGFβ were not suited for predicting disease recurrence after curative surgery for NSCLC. However, the combined biomarker score was significantly associated with OS. The score may give an indication of the immunological status of the patient, which could be useful for pre- or post-surgery assessment, in relation to immunotherapy or other oncologic treatments if future studies can prove clinical utility.
- Open Access
- 10 July 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e004382
Sing-a-Lung 2.0: protocol for a multicentre randomised controlled trial to investigate the effects and mechanisms of online-delivered singing training versus usual care 6–18 months after surgical resection for non-small cell lung cancer (NSCLC)
Introduction: Patients who have undergone curative surgery for non-small cell lung cancer (NSCLC) often experience long-term reduced quality of life (QoL), high symptom burden, risk of physical deconditioning and comorbidity. Current Danish rehabilitation offers are heterogeneous and not specifically tailored to the disease-specific needs and no long-term targeted support is currently available. Previously, singing—delivered as a structured training modality—has conferred both physiological and psychological improvements in chronic obstructive pulmonary disease, which may likely be transferable to NSCLC, as the two conditions share overlapping symptoms and characteristics. We aim to explore whether a singing-based intervention improves physical function, QoL and symptom burden 6–18 months postsurgery in NSCLC. Moreover, we aim to explore the underpinning physiological mechanisms of singing. Methods and analysis: We will conduct a multicentre randomised controlled trial, comparing 10 weeks’ online-delivered structured singing training to usual care. Trial outcomes include primary outcome, physical capacity (measure: Six-Minute Walking Test), and secondary outcomes, QoL and symptoms (measures: St. George’s Respiratory Questionnaire (SGRQ); the European Organisation for Research and Treatment of Cancer Questionnaire (QLQ-C30; QLQ-LC13); Hospital Anxiety and Depression Scale (HADS) and airway physiology (measure: forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC)). Explorative outcomes include aerobic fitness/maximal oxygen uptake (VO 2 -max); exercise-induced adaptations; respiratory muscle strength and control; inflammatory biomarkers. Analysis: Descriptive statistics, stratified analyses, regression models and association and independence between objective and subjective outcomes. Ethics and dissemination: The trial was approved by the Committee on Health Research Ethics (SJ-1027) and the Danish Act on Processing of Personal Data (p-2024-19634). Results will be reported in peer-reviewed scientific journals. Trial registration number: NCT07460999 .
- 10 July 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e004382
Open AccessSing-a-Lung 2.0: protocol for a multicentre randomised controlled trial to investigate the effects and mechanisms of online-delivered singing training versus usual care 6–18 months after surgical resection for non-small cell lung cancer (NSCLC)
Introduction: Patients who have undergone curative surgery for non-small cell lung cancer (NSCLC) often experience long-term reduced quality of life (QoL), high symptom burden, risk of physical deconditioning and comorbidity. Current Danish rehabilitation offers are heterogeneous and not specifically tailored to the disease-specific needs and no long-term targeted support is currently available. Previously, singing—delivered as a structured training modality—has conferred both physiological and psychological improvements in chronic obstructive pulmonary disease, which may likely be transferable to NSCLC, as the two conditions share overlapping symptoms and characteristics. We aim to explore whether a singing-based intervention improves physical function, QoL and symptom burden 6–18 months postsurgery in NSCLC. Moreover, we aim to explore the underpinning physiological mechanisms of singing. Methods and analysis: We will conduct a multicentre randomised controlled trial, comparing 10 weeks’ online-delivered structured singing training to usual care. Trial outcomes include primary outcome, physical capacity (measure: Six-Minute Walking Test), and secondary outcomes, QoL and symptoms (measures: St. George’s Respiratory Questionnaire (SGRQ); the European Organisation for Research and Treatment of Cancer Questionnaire (QLQ-C30; QLQ-LC13); Hospital Anxiety and Depression Scale (HADS) and airway physiology (measure: forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC)). Explorative outcomes include aerobic fitness/maximal oxygen uptake (VO 2 -max); exercise-induced adaptations; respiratory muscle strength and control; inflammatory biomarkers. Analysis: Descriptive statistics, stratified analyses, regression models and association and independence between objective and subjective outcomes. Ethics and dissemination: The trial was approved by the Committee on Health Research Ethics (SJ-1027) and the Danish Act on Processing of Personal Data (p-2024-19634). Results will be reported in peer-reviewed scientific journals. Trial registration number: NCT07460999 .
- Open Access
- 8 July 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e003865
Patient-reported outcomes after surgical resection for non-small cell lung cancer and perceptions of postsurgical rehabilitation programmes
Background: Surgical resection is essential in the treatment of early-stage non-small cell lung cancer (NSCLC), followed by rehabilitation with physical exercise training to improve physical capacity, quality of life (QoL) and symptom burden. In Denmark, rehabilitation is municipality-based and not disease-specific and without a maintenance model. We aimed to investigate QoL and symptoms 6–12 months after NSCLC surgery, hypothesising impaired QoL and symptom levels. Moreover, we explored rehabilitation attendance. Methods: An observational, cross-sectional, survey-based study was conducted from March to June 2025 across two Danish regions in patients after surgery for stage I or II NSCLC and without adjuvant oncological treatment (preregistration: osf.io/vmpft). Each site contacted their own eligible patients via digital mail. Registry data from the Danish Lung Cancer Registry and electronic patient registries: socio-demographics, disease-specific characteristics and surgical procedure. Survey data: QoL and symptoms burden (measure: The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30; Reporting: Raw and transformed scores and dichotomised according to defined thresholds and cut-offs for clinical importance) and self-reported information about rehabilitation attendance. Data analyses: descriptive and stratified analyses. Results: We identified 168 patients, 94 (56% of 168) were eligible and 67 (71% of 94) responded to the survey. No differences were found in baseline characteristics and overall mean time since surgery was 8.9±1.8 months. Current QoL and symptoms were clinically impaired (eg, physical functioning: 51%; dyspnoea: 70%). Around half (54%) reported having attended a rehabilitation programme and those having attended were more likely to have clinically impaired physical functioning and dyspnoea at present. Conclusions: QoL and symptoms were impaired 6–12 months after NSCLC surgery, and the current level did not seem to be related to having attended a postsurgical rehabilitation programme. Disease-specific challenges should be addressed in future rehabilitation and maintenance models.
- 8 July 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e003865
Open AccessPatient-reported outcomes after surgical resection for non-small cell lung cancer and perceptions of postsurgical rehabilitation programmes
Background: Surgical resection is essential in the treatment of early-stage non-small cell lung cancer (NSCLC), followed by rehabilitation with physical exercise training to improve physical capacity, quality of life (QoL) and symptom burden. In Denmark, rehabilitation is municipality-based and not disease-specific and without a maintenance model. We aimed to investigate QoL and symptoms 6–12 months after NSCLC surgery, hypothesising impaired QoL and symptom levels. Moreover, we explored rehabilitation attendance. Methods: An observational, cross-sectional, survey-based study was conducted from March to June 2025 across two Danish regions in patients after surgery for stage I or II NSCLC and without adjuvant oncological treatment (preregistration: osf.io/vmpft). Each site contacted their own eligible patients via digital mail. Registry data from the Danish Lung Cancer Registry and electronic patient registries: socio-demographics, disease-specific characteristics and surgical procedure. Survey data: QoL and symptoms burden (measure: The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30; Reporting: Raw and transformed scores and dichotomised according to defined thresholds and cut-offs for clinical importance) and self-reported information about rehabilitation attendance. Data analyses: descriptive and stratified analyses. Results: We identified 168 patients, 94 (56% of 168) were eligible and 67 (71% of 94) responded to the survey. No differences were found in baseline characteristics and overall mean time since surgery was 8.9±1.8 months. Current QoL and symptoms were clinically impaired (eg, physical functioning: 51%; dyspnoea: 70%). Around half (54%) reported having attended a rehabilitation programme and those having attended were more likely to have clinically impaired physical functioning and dyspnoea at present. Conclusions: QoL and symptoms were impaired 6–12 months after NSCLC surgery, and the current level did not seem to be related to having attended a postsurgical rehabilitation programme. Disease-specific challenges should be addressed in future rehabilitation and maintenance models.
- Open Access
- 28 April 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Long-term risk of depression in lung, colon, breast, and prostate cancer: a 25-year nationwide comparative study
Depression is common among patients with cancer, but its occurrence may vary across cancer types with differing prognoses and symptom burdens. This nationw
- 28 April 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessLong-term risk of depression in lung, colon, breast, and prostate cancer: a 25-year nationwide comparative study
Depression is common among patients with cancer, but its occurrence may vary across cancer types with differing prognoses and symptom burdens. This nationw
- Open Access
- 6 January 2026
- Published by Elsevier in Journal of Cancer Policy
- Vol. 47, 100703
Current opinions on lung cancer screening in the Nordic countries: A survey-based study
- 6 January 2026
- Published by Elsevier in Journal of Cancer Policy
- Vol. 47, 100703
Open AccessCurrent opinions on lung cancer screening in the Nordic countries: A survey-based study
- 4 January 2026
- Published by Wiley in Clinical Otolaryngology
- Vol. 51 (3) , 394-400
Adherence and Effect on Allergy Medication Use in Allergic Rhinoconjunctivitis Patients Treated With House Dust Mite Allergen Immunotherapy—A Nationwide Cohort Study
Introduction: House dust mite (HDM) allergy significantly impacts quality of life. Allergen immunotherapy (AIT), specifically sublingual immunotherapy (SLIT), is an effective treatment for HDM allergy, but adherence to SLIT remains a challenge. This study aimed to evaluate the impact of adherence to SLIT on the use of allergy medications, including antihistamines, nasal corticosteroids, and inhaled corticosteroids (ICS) in a real‐world setting. Methods: We conducted a nationwide cohort study using data from Denmark's comprehensive registries. Patients who initiated HDM SLIT between 2015 and 2020 were included, with follow‐up through 2022. Adherent patients, defined as those obtaining at least 80% of the prescribed Defined Daily Dose ( DDD ) of SLIT , were compared to non‐adherent patients. Medication use was tracked for antihistamines, nasal corticosteroids, and ICS . Statistical analyses, including Probit and generalised linear models, assessed the likelihood of obtaining medications and the quantity dispensed, adjusted for age and sex. Results: Of 950 patients, 456 (48%) were classified as adherent. Adherent patients showed significantly reduced usage of antihistamines ( p < 0.001) and nasal corticosteroids ( p < 0.001) compared to non‐adherent patients. No significant differences were found in ICS use or dosage. Additionally, adherent patients were more likely to have higher education levels and be married or cohabiting. Conclusion: Adherence to SLIT for HDM allergy is associated with reduced use of antihistamines and nasal corticosteroids. These findings emphasise the importance of SLIT adherence in managing HDM allergy and suggest that improving adherence could further reduce medication usage, improving patient outcomes in real‐world settings.
- 4 January 2026
- Published by Wiley in Clinical Otolaryngology
- Vol. 51 (3) , 394-400
Adherence and Effect on Allergy Medication Use in Allergic Rhinoconjunctivitis Patients Treated With House Dust Mite Allergen Immunotherapy—A Nationwide Cohort Study
Introduction: House dust mite (HDM) allergy significantly impacts quality of life. Allergen immunotherapy (AIT), specifically sublingual immunotherapy (SLIT), is an effective treatment for HDM allergy, but adherence to SLIT remains a challenge. This study aimed to evaluate the impact of adherence to SLIT on the use of allergy medications, including antihistamines, nasal corticosteroids, and inhaled corticosteroids (ICS) in a real‐world setting. Methods: We conducted a nationwide cohort study using data from Denmark's comprehensive registries. Patients who initiated HDM SLIT between 2015 and 2020 were included, with follow‐up through 2022. Adherent patients, defined as those obtaining at least 80% of the prescribed Defined Daily Dose ( DDD ) of SLIT , were compared to non‐adherent patients. Medication use was tracked for antihistamines, nasal corticosteroids, and ICS . Statistical analyses, including Probit and generalised linear models, assessed the likelihood of obtaining medications and the quantity dispensed, adjusted for age and sex. Results: Of 950 patients, 456 (48%) were classified as adherent. Adherent patients showed significantly reduced usage of antihistamines ( p < 0.001) and nasal corticosteroids ( p < 0.001) compared to non‐adherent patients. No significant differences were found in ICS use or dosage. Additionally, adherent patients were more likely to have higher education levels and be married or cohabiting. Conclusion: Adherence to SLIT for HDM allergy is associated with reduced use of antihistamines and nasal corticosteroids. These findings emphasise the importance of SLIT adherence in managing HDM allergy and suggest that improving adherence could further reduce medication usage, improving patient outcomes in real‐world settings.
- Open Access
- 25 December 2025
- Published by Wiley in Psycho-Oncology
- Vol. 34 (12) , e70371
Changes in Depressive Patterns Before and After Lung Cancer Diagnosis: A Nationwide Population‐Based Study
Objective: Depression is common among patients with lung cancer, but evidence from large, population‐based studies is limited. This study examined antidepressant use and hospital‐diagnosed depression before and after lung cancer diagnosis in Denmark. Methods: We conducted a nationwide registry‐based study including all patients diagnosed with lung cancer from 1998 to 2022 and a comparison cohort (1:4 ratio) matched on age, sex, municipality, and marital/cohabiting status. Data on hospital diagnoses and redeemed antidepressant prescriptions were obtained from Danish national registries. Results: Among 73,930 patients with lung cancer and 293,892 matched comparison subjects, antidepressant use was already higher among lung cancer patients two years before diagnosis (12.7% vs. 9.9%) and increased markedly after diagnosis (23.7% vs. 11.9% 2 years post‐diagnosis, p < 0.001). Among individuals without prior antidepressant use, 8.4% of patients with lung cancer initiated antidepressants within the first year and 13.7% within the second year, compared with 1.9% and 3.4% of controls ( p < 0.001). Hospital‐diagnosed depression occurred in 2.1% of lung cancer patients versus 0.8% of controls, with higher rates among females. Conclusions: Antidepressant use is prevalent before, and rises further after, a lung cancer diagnosis. The difference relative to the comparison cohort was most evident among individuals with no history of antidepressant use. These findings underscore the need for systematic psychosocial assessment and integrated mental health support throughout the lung cancer care pathway.
- 25 December 2025
- Published by Wiley in Psycho-Oncology
- Vol. 34 (12) , e70371
Open AccessChanges in Depressive Patterns Before and After Lung Cancer Diagnosis: A Nationwide Population‐Based Study
Objective: Depression is common among patients with lung cancer, but evidence from large, population‐based studies is limited. This study examined antidepressant use and hospital‐diagnosed depression before and after lung cancer diagnosis in Denmark. Methods: We conducted a nationwide registry‐based study including all patients diagnosed with lung cancer from 1998 to 2022 and a comparison cohort (1:4 ratio) matched on age, sex, municipality, and marital/cohabiting status. Data on hospital diagnoses and redeemed antidepressant prescriptions were obtained from Danish national registries. Results: Among 73,930 patients with lung cancer and 293,892 matched comparison subjects, antidepressant use was already higher among lung cancer patients two years before diagnosis (12.7% vs. 9.9%) and increased markedly after diagnosis (23.7% vs. 11.9% 2 years post‐diagnosis, p < 0.001). Among individuals without prior antidepressant use, 8.4% of patients with lung cancer initiated antidepressants within the first year and 13.7% within the second year, compared with 1.9% and 3.4% of controls ( p < 0.001). Hospital‐diagnosed depression occurred in 2.1% of lung cancer patients versus 0.8% of controls, with higher rates among females. Conclusions: Antidepressant use is prevalent before, and rises further after, a lung cancer diagnosis. The difference relative to the comparison cohort was most evident among individuals with no history of antidepressant use. These findings underscore the need for systematic psychosocial assessment and integrated mental health support throughout the lung cancer care pathway.
- 13 October 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (1) , 103-105
Adherence to Grass Pollen Allergen Immunotherapy and Allergy Medication Use in Patients With Allergic Rhinitis
- 13 October 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (1) , 103-105
Adherence to Grass Pollen Allergen Immunotherapy and Allergy Medication Use in Patients With Allergic Rhinitis